GB Sciences has decided to focus its drug development forces on three cannabinoid therapies in its pipeline, and it has tapped Worldwide Clinical Trials to assess its intellectual property portfolio and to help with pre-IND planning.
Through its subsidiary Growblox Life Sciences formed last July, the company is planning a pilot human studies in Nevada for two formulations for Pakinson’s disease and chronic pain, respectively, with future IND-enabled clinical trials in other states; while another cardiovascular candidate will be directly put to FDA-registered IND after preclinical studies.
Sales of whole marijuana for nonmedical use has been legalized in Nevada since July 1 after the state legislators passed a bill last November, while access to medicinal cannabis allowed among people with certain conditions within the state dated way back to 2001.
Instead of whole plants, the drug candidates that the life sciences arm of GB Sciences develops are actually extractions. The company touts that its